WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 200250
CAS#: 3432-99-3
Description: ANX-510 is a folate-based biomodulator with potential antineoplastic activity. 5,10-methylenetetrahydrofolate (MTHF) stabilizes the covalent binding of the fluorouracil metabolite 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate (FdUMP) to its target enzyme, thymidylate synthase, which results in inhibition of thymidylate synthase, depletion of thymidine triphosphate (TTP), a necessary constituent of DNA, and tumor cell death. Unlike leucovorin, MTHF, as the active form of folate, does not require metabolic activation and may increase the chemotherapeutic effects of fluorouracil with lower toxicity.
MedKoo Cat#: 200250
Name: ANX-510
CAS#: 3432-99-3
Chemical Formula: C20H23N7O6
Exact Mass: 457.17098
Molecular Weight: 457.44
Elemental Analysis: C, 52.51; H, 5.07; N, 21.43; O, 20.99
ANX-510, purity > 98%, is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2to inquire quote.
Synonym: ANX510CoFactor. 510methylenetetrahydrofolate510Methylene5678tetrahydrofolate510MTHFMTHF
IUPAC/Chemical Name: (2S)-2-(4-(3-amino-1-oxo-5,6,6a,7-tetrahydroimidazo[1,5-f]pteridin-8(1H,4H,9H)-yl)benzamido)pentanedioic acid.
InChi Key: QYNUQALWYRSVHF-ABLWVSNPSA-N
InChi Code: InChI=1S/C20H23N7O6/c21-20-24-16-15(18(31)25-20)27-9-26(8-12(27)7-22-16)11-3-1-10(2-4-11)17(30)23-13(19(32)33)5-6-14(28)29/h1-4,12-13H,5-9H2,(H,23,30)(H,28,29)(H,32,33)(H4,21,22,24,25,31)/t12?,13-/m0/s1
SMILES Code: O=C(O)[C@@H](NC(C1=CC=C(N2CN3C4=C(NC(N)=NC4=O)NCC3C2)C=C1)=O)CCC(O)=O
The following data is based on the product molecular weight 457.44 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1. Costantini, Carrie L.; Reid, Tony R.; Bouvet, Michael. Resection of hepatic metastasis after 5-fluorouracil and CoFactor for colon cancer. Hepato-Gastroenterology (2009), 56(91-92), 645-649. CODEN: HEGAD4 ISSN:0172-6390. CAN 152:183523 AN 2009:892897
2. Schlemmer, Marcus; Kuehl, Michael; Schalhorn, Andreas; Rauch, Josefine; Jauch, Karl-W.; Hentrich, Marcus. Tissue Levels of Reduced Folates in Patients with Colorectal Carcinoma After Infusion of Folinic Acid at Various Dose Levels. Clinical Cancer Research (2008), 14(23), 7930-7934. CODEN: CCREF4 ISSN:1078-0432. CAN 150:555085 AN 2008:1433512
3. Etienne-Grimaldi, Marie-Christine; Francoual, Mireille; Formento, Jean-Louis; Milano, Gerard. Methylenetetrahydrofolate reductase (MTHFR) variants and fluorouracil-based treatments in colorectal cancer. Pharmacogenomics (2007), 8(11), 1561-1566. CODEN: PARMFL ISSN:1462-2416. CAN 148:298717 AN 2008:73337
4. Sakamoto, Etsuko; Tsukioka, Sayaka; Oie, Shinji; Kobunai, Takashi; Tsujimoto, Hiroaki; Sakamoto, Kazuki; Okayama, Yoshihiro; Sugimoto, Yoshikazu; Oka, Toshinori; Fukushima, Masakazu; Oka, Tatsuzo. Folylpolyglutamate synthase and -glutamyl hydrolase regulate leucovorin-enhanced 5-fluorouracil anticancer activity. Biochemical and Biophysical Research Communications (2008), 365(4), 801-807. CODEN: BBRCA9 ISSN:0006-291X. CAN 148:112627 AN 2007:1447179
5. Guillem, V. M.; Collado, M.; Terol, M. J.; Calasanz, M. J.; Esteve, J.; Gonzalez, M.; Sanzo, C.; Nomdedeu, J.; Bolufer, P.; Lluch, A.; Tormo, M. Role of MTHFR (677, 1298) haplotype in the risk of developing secondary leukemia after treatment of breast cancer and hematological malignancies. Leukemia (2007), 21(7), 1413-1422. CODEN: LEUKED ISSN:0887-6924. CAN 148:182768 AN 2007:661505
6. Lu, Wenyun; Kwon, Yun Kyung; Rabinowitz, Joshua D. Isotope Ratio-Based Profiling of Microbial Folates. Journal of the American Society for Mass Spectrometry (2007), 18(5), 898-909. CODEN: JAMSEF ISSN:1044-0305. CAN 147:26286 AN 2007:481559
7. Brody, Jonathan R.; Gallmeier, Eike; Yoshimura, Kiyoshi; Hucl, Tomas; Kulesza, Peter; Canto, Marcia I.; Hruban, Ralph H.; Schulick, Richard D.; Kern, Scott E. A proposed clinical test for monitoring fluoropyrimidine therapy: detection and stability of thymidylate synthase ternary complexes. Cancer Biology & Therapy (2006), 5(8), 923-927. CODEN: CBTAAO ISSN:1538-4047. CAN 146:197623 AN 2006:1343787
8. Saif, Muhammad Wasif; Merritt, James; Robbins, Joan; Stewart, Jeffrey; Schupp, Joachim. Phase III multicenter randomized clinical trial to evaluate the safety and efficacy of CoFactor/5-fluorouracil/bevacizumab versus leucovorin/5-fluorouracil/bevacizumab as initial treatment for metastatic colorectal carcinoma. Clinical Colorectal Cancer (2006), 6(3), 229-234. CODEN: CCCLCF ISSN:1533-0028. CAN 146:176394 AN 2006:1166445
9. Chattopadhyay, Shrikanta; Zhao, Rongbao; Krupenko, Sergey A.; Krupenko, Natalia; Goldman, I. David. The inverse relationship between reduced folate carrier function and Pemetrexed activity in a human colon cancer cell line. Molecular Cancer Therapeutics (2006), 5(2), 438-449. CODEN: MCTOCF ISSN:1535-7163. CAN 144:403910 AN 2006:183633
10. Tan, Xiao-Jian; Carlson, Heather A. Docking Studies and Ligand Recognition in Folylpolyglutamate Synthetase. Journal of Medicinal Chemistry (2005), 48(24), 7764-7772. CODEN: JMCMAR ISSN:0022-2623. CAN 144:65904 AN 2005:1163384